-
U.S. $772.5B Pharmacy Spend in 2023 Driven by Weight-Loss Drugs
24 Apr 2024 17:58 GMT
… selling drug in the nation, replacing the autoimmune disease drug adalimumab, … expenditures, mail-order pharmacies accounted for $206. … drugs come to market and as the FDA approves the medications … medications such as Remdesivir to cheaper oral treatments, …
-
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
24 Apr 2024 20:01 GMT
… proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) … development to approval in the US, EU, and UK for the treatment … rights acquired by Napp Pharmaceutical Group Limited, a … oncologic, viral and autoimmune diseases. Cidara is headquartered in …
-
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
24 Apr 2024 20:05 GMT
… trial. CD388 is a long-acting antiviral investigational drug invented and developed … transforming existing treatment and prevention paradigms … , viral and autoimmune diseases. Cidara is headquartered … Agreement between Janssen Pharmaceuticals, Inc., a …
-
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24 Apr 2024 11:00 GMT
… wide range of autoimmune diseases that has been difficult to drug with conventional … who suffer from autoimmune disease.” Jonathan Zalevsky, Chief Research and Development Officer of …
-
Samsung Bioepis Earns European License for Autoimmune Disease Drug
24 Apr 2024 09:49 GMT
… original drug Stellara was developed by Janssen. It is a treatment for autoimmune diseases such … autoimmune disease treatments to include interleukin inhibitors in addition to its three existing autoimmune disease treatments …
-
Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?
24 Apr 2024 14:28 GMT
… to developing new drugs and therapies … 45% of global pharmaceutical revenues, has … pharmaceutical companies to develop innovative treatments and medications … medications like Humira, Skyrizi, and Imbruvica, addressing conditions ranging from autoimmune diseases …
-
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 Apr 2024 14:00 GMT
… Drug designations by the FDA. Additional information on the ANTLER trial … biopharmaceutical company dedicated to developing transformative therapies for patients … available treatments for patients with hematologic malignancies and autoimmune diseases. Follow …
-
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
24 Apr 2024 12:00 GMT
… positive Phase 3 RESILIENT trial of Tonmya™ (also … treatment of autoimmune diseases. Tonix also has product candidates in development … .S. Food and Drug Administration (FDA) as the tradename … . As with any pharmaceutical under development, there are significant …
-
University of Birmingham: B Cells’ Potential in Fighting Cancer or Autoimmune Diseases Through Targeting Mitochondrial Metabolism Explored
23 Apr 2024 17:23 GMT
… fight cancers and to treat autoimmune diseases by either increasing … potential therapeutic target for autoimmune diseases.
In addition, the … for autoimmune and cancer treatment. They are also … by supporting the development of other inflammatory immune …
-
European Commission gives nod to Sandoz’s biosimilar to treat autoimmune disorders
23 Apr 2024 10:32 GMT
Sandoz, a key player in generic and biosimilar medicines, announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis.
According to the company’s …